Fangsheng Pharmaceutical Group 1.1 new chemical drug diantikang sodium for injection approved clinical
-
Last Update: 2015-08-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the latest information from CFDA, a new chemical drug with acceptance No "cxhl1301089 Xiang" of Fangsheng pharmaceutical has been approved for clinical application At present, the processing status is changed to "certificate preparation completed - pending approval" It is found that the product is diantikang sodium for injection, which belongs to class 1.1 chemical new drug It is a derivative of camptothecin and used for anti-tumor This product was applied for acceptance in the drug administration in December 2013 In 2014, the annual report disclosed that the company's research project "phase I and phase II clinical research of diantikang on colorectal cancer" was approved as a major national new drug creation project Some analysts pointed out that this kind of anti-tumor drugs will become a "nuclear weapon" for Hunan Fangsheng pharmaceutical to seize the national and even global market.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
